Orion Corporation, Orion Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Orion Corporation, Orion Pharma sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Orion Corporation, Orion Pharma: 7 sponsored US clinical trials, 2 recruiting.
Orion Corporation, Orion Pharma sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer Metastatic, with 1 trials.
Upper-quartile sponsor footprint
Orion Corporation, Orion Pharma sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT03436485
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
NCT03948178
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
NCT03505021
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
NCT01429064
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
NCT01317641
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Orion Corporation, Orion Pharma pipeline
2 recruiting of 7 indexed (29% open); 3 completed (43%).
Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer Metastatic (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Orion Corporation, Orion Pharma: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Orion Corporation, Orion Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Orion Corporation, Orion Pharma page
7 registered trials is a research-attention snapshot, not an endorsement of Orion Corporation, Orion Pharma or any single study.
- 2 of Orion Corporation, Orion Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer Metastatic is the condition Orion Corporation, Orion Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer Metastatic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Orion Corporation, Orion Pharma pipeline card: 7 registered trials from official public datasets.Report a data error.